CYCLIN E1 AMPLIFICATION IN ADVANCED BC

In this study, researchers focused on cyclin-E1 amplified breast cancer, found in approximately 3-7% of cases. This subset exhibited distinct clinical, pathological, and genomic characteristics. 

Patients with cyclin-E1 amplification had poor outcomes when treated with first-line CDK4/6 inhibitors plus endocrine therapy for HR+/ HER2- tumours and with THP for HER2+ tumours. Additionally, preclinical models showed that PKMYT1 inhibitors and CDK-2 selective inhibitors were effective against cyclin-E1 amplified breast cancer. The next phase involves clinical trials to evaluate these targeted therapies, aiming to provide new treatment options for this patient group.